Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Tony Reiman, MD, Kerry J. Savage, MD MSc, Michael Crump, MD, Matthew Cheung, MD, David A. MacDonald, MD, Rena Buckstein, MD, Stephen Couban, MD, Eugenia Piliotis, MD, Kevin R Imrie, MD, David Spaner, MD PhD, Sudeep Shivakumar, MD, John Kuruvilla, MD, Diego Villa, Lois E. Shepherd, MD, Tanya Skamene, MD, Chad Winch, Bingshu E Chen, PhD, Annette E Hay, MB ChB

Blood (2016) 128 (22): 4162.

https://doi.org/10.1182/blood.V128.22.4162.4162

Published: 2016

Journal Articles

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

John Kuruvilla, David A. MacDonald, C. Tom Kouroukis, Matthew Cheung, Harold J. Olney, A. Robert Turner, Peter Anglin, Matthew Seftel, Walid Sabry Ismail, Stefano Luminari, Stephen Couban, Tara Baetz, Ralph M. Meyer, Annette E. Hay, Lois Shepherd, Marina S. Djurfeldt, Sameer Alamoudi, Bingshu E. Chen, Michael Crump

Blood (2015) 126 (6): 733–738.

https://doi.org/10.1182/blood-2015-01-622084

Published: 2015

Journal Articles

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

Randeep Sangha, Andrew Davies, PhD, Nam H. Dang, MD, PhD, Michinori Ogura, MD, PhD, David A. MacDonald, MD, Angela Volkert, Revathi Ananthakrishnan, Kenneth Luu, Joseph P. Boni, PhD, Erik Vandendries, MD, Yeow-Tee YT Goh, MD

Blood (2013) 122 (21): 1821.

https://doi.org/10.1182/blood.V122.21.1821.1821

Published: 2013

Journal Articles

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

Blood (2013) 122 (21): 155.

https://doi.org/10.1182/blood.V122.21.155.155

Published: 2013

Journal Articles

An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data

Michinori Ogura, MD, PhD, Kiyohiko Hatake, Andrew Davies, MD, Michael Crump, MD, FRCPC, Kensei Tobinai, MD, PhD, Mitchell R Smith, MD, PhD, Fritz Offner, Shaw-Ling Wang, Taro Ishibashi, Luisa Paccagnella, Erik Vandendries, David A MacDonald

Blood (2012) 120 (21): 1633.

https://doi.org/10.1182/blood.V120.21.1633.1633

Published: 2012

Journal Articles

An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,

Michinori Ogura, Toshiki Uchida, David A MacDonald, Kiyohiko Hatake, Andrew Davies, Randeep Sangha, Michael Crump, MD, FRCPC, Catherine Thieblemont, MD, Taro Ishibashi, Steven Hua, Luisa Paccagnella, Erik R Vandendries, MD, PhD, Yukio Kobayashi, Kensei Tobinai, MD

Blood (2011) 118 (21): 3715.

https://doi.org/10.1182/blood.V118.21.3715.3715

Published: 2011

Journal Articles

Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group.

Rena Buckstein, MD, John Kuruvilla, MD, Neil Chua, MD, Christina Lee, David A Macdonald, MD, Abdulwahab J. Al-Tourah, MD, Alison Foo, Wendy Walsh, S. Percy Ivy, MD, Michael Crump, MD, Elizabeth Eisenhauer, MD

Blood (2009) 114 (22): 2729.

https://doi.org/10.1182/blood.V114.22.2729.2729

Published: 2009

Journal Articles

Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.

Laurie H. Sehn, MD, MPH, David A Macdonald, MD, Sheldon H. Rubin, MD, Guy Cantin, MD, Morel Rubinger, MD, Bernard Lemieux, MD, Sanraj Basi, MD, Kevin R Imrie, MD, Randy D. Gascoyne, Bingshu Chen, PhD, Marina Djurfeldt, MSc, Lois Shepherd, MD, Stephen Couban, MD, Michael Crump, MD

Blood (2009) 114 (22): 407.

https://doi.org/10.1182/blood.V114.22.407.407

Published: 2009

Journal Articles

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial

Darrell J White, MD, Nizar J Bahlis, MD, Deborah C Marcellus, MD, Andrew Belch, MD, A. Keith Stewart, MBChB, MBA, Christine Chen, MD, Michael J Kovacs, MD, David A Macdonald, MD, Donna E Reece, MD, Erica Harnett, MSc, Judy-Anne W Chapman, PhD, Ralph M Meyer, MD

Blood (2008) 112 (11): 2767.

https://doi.org/10.1182/blood.V112.11.2767.2767

Published: 2008

Journal Articles

Tolerability and Efficacy of Bortezomib Added to CVP-R for Previously Untreated Advanced Stage Follicular Lymphoma: Interim Analysis of a Phase II Study by the NCIC Clinical Trials Group.

Laurie H Sehn, MD, MPH, David A Macdonald, MD, Sheldon H. Rubin, MD, Morel Rubinger, MD, FRCPC, Kevin R Imrie, MD, Judy-Anne W Chapman, PhD, Marina Djurfeldt, Lois Shepherd, MD, Stephen Couban, MD, Michael Crump, MD

Blood (2008) 112 (11): 1576.

https://doi.org/10.1182/blood.V112.11.1576.1576

Published: 2008

Journal Articles

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.

Darrell J. White, MD, Michael J. Kovacs, MD, Andrew Belch, MD, Keith Stewart, MB, ChB, Christine Chen, MD, Sheldon Rubin, MD, David A. Macdonald, MD, Erica Harnett, MSc, Judy-Anne W. Chapman, PhD, Lois E. Shepherd, MD, Ralph M. Meyer, MD

Blood (2007) 110 (11): 189.

https://doi.org/10.1182/blood.V110.11.189.189

Published: 2007

Journal Articles

Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).

David A. Macdonald, MD, Mary K. Gospodarowicz, MD, Woodrow A. Wells, MD, Robert G. Pearcey, MD, Joseph M. Connors, MD, Jane N. Winter, MD, Sandra J. Horning, MD, Marina S. Djurfeldt, MSc, Keyue Ding, PhD, Lois E. Shepherd, MD, Ralph M. Meyer, MD

Blood (2005) 106 (11): 817.

https://doi.org/10.1182/blood.V106.11.817.817

Published: 2005

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

A Phase I Study of Romidepsin, Gemcitabine, Dexamethasone and Cisplatin Combination Therapy in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma: Canadian Cancer Trials Group Study LY.15

Salvage chemotherapy and autologous stem cell transplantation for transformed indolent lymphoma: a subset analysis of NCIC CTG LY12

Phase I Study Of Inotuzumab Ozogamicin (InO) Combined With R-GDP For Relapsed/Refractory CD22+ B-Cell Non-Hodgkin Lymphoma (B-NHL)

A Randomized Trial Of Rituximab Vs Observation Following Autologous Stem Cell Transplantation (ASCT) For Relapsed Or Refractory CD20-Positive B Cell Lymphoma: Final Results Of NCIC CTG LY.12

An Open-Label, Phase 1 Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with CD22-Positive B-Cell Non-Hodgkin's Lymphoma: Preliminary Safety and Efficacy Data

An Open-Label, Phase I Study of R-CVP in Combination with Inotuzumab Ozogamicin in Patients with Relapsed/Refractory CD22-Positive B-Cell Non-Hodgkin Lymphoma,

Sunitinib in Relapsed or Refractory Diffuse Large B Cell Lymphoma: Results of a Phase II Multi-Center Study of the NCIC Clinical Trials Group.

Bortezomib Added to CVP-R Is Safe and Effective for Previously Untreated Advanced Stage Follicular Lymphoma: A Phase II Study by the NCIC Clinical Trials Group.

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: The NCIC CTG MY.11 Trial

Tolerability and Efficacy of Bortezomib Added to CVP-R for Previously Untreated Advanced Stage Follicular Lymphoma: Interim Analysis of a Phase II Study by the NCIC Clinical Trials Group.

Phase II Testing of Lenalidomide Plus Melphalan for Previously Untreated Older Patients with Multiple Myeloma: Toxicity Data from the NCIC CTG MY.11 Trial.

Relapse Patterns and Subsequent Outcomes of Patients Treated on the NCIC CTG HD.6 (ECOG JHD06) Randomized Trial Evaluating ABVD Alone in Patients with Limited Stage Hodgkin Lymphoma (HL).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only